Table 1.
Characteristics of Included Studiesa
| Author (Mid-Year) | Country | Study Design | Type of Bacteria | Mortality (Days) | Patients Received BL/BLIs as Definitive Therapy | Patients Received Carbapenems as Definitive Therapy | Patients Treated Empirically With BL/BLIs | Patients Treated Empirically With Carbapenems |
|---|---|---|---|---|---|---|---|---|
| Deceased/studied | Deceased/studied | Deceased/studied | Deceased/studied | |||||
| Gutiérrez- Gutiérrez et al (2009) [15] | Multicenterb | Retrospective | Enterobacteriaceae | 30 | 9/92 | 71/509 | 30/170 | 39/195 |
| Bin et al (2004) [16] | China | Prospective | Escherichia coli | 30 | 0/2 | 0/8 | 0/2 | 0/3 |
| Chaubey et al (2004) [17] | Canada | Retrospective | E coli or Klebsiella pneumoniae | NA | 6/28 | 4/30 | 6/16 | 0/10 |
| Cheng et al (2006) [18] | China (Taiwan) | Retrospective | E coli or K pneumoniae | 30 | NA | NA | 0/4 | 10/39 |
| Chopra et al (2007) [19] | United States of America | Retrospective | E coli or K pneumoniae | NA | 7/18 | 12/33 | NA | NA |
| Gudiol et al (2007) [20] | Spain | Prospective | E coli | 30 | 2/2 | 3/14 | 3/6 | 2/5 |
| Kang et al (2009) [21] | Republic of Korea | Retrospective | E coli or K pneumoniae | 30 | NA | NA | 8/36 | 21/78 |
| Lee et al (2005) [22] | China (Taiwan) | Retrospective | Enterobacter cloacae | 28 | 3/3 | 5/53 | 1/13 | 4/24 |
| Metan et al (2005) [23] | Turkey | Retrospective | E coli | 14 | NA | NA | 5/7 | 7/22 |
| Ng et al (2012) [24] | Singapore | Retrospective | E coli or K pneumoniae | 30 | NA | NA | 29/94 | 17/57 |
| Qureshi et al (2007) [25] | United States of America | Retrospective | E cloacae | 28 | NA | NA | 1/4 | 0/8 |
| Rodŕıguez- Bano et al (2004) [26] | Spain | Prospective | E coli | 30 | 5/54 | 20/120 | 7/72 | 6/31 |
| To et al (2008) [27] | China | Retrospective | E coli | 30 | NA | NA | 15/74 | 14/47 |
| Tumbarello et al (2002) [28] | Italy | Retrospective | E coli or K pneumoniae or Proteus mirabilis | 21 | NA | NA | 4/33 | 1/28 |
Abbreviations: BL/BLIs, β-lactam/β-lactamase inhibitor; BSI, bloodstream infection; ESBL, extended spectrum β-lactamase; ESBL-PE, ESBL-producing Enterobacteriaceae; NA, not applicable.
aCollected data (first author, mid year, country, study design, ESBL-PE species, number of patients with ESBL-PE BSI that received empiric and/or definitive therapy with carbapenems or BL/BLIs, and among them, the number of patients who died).
bAfrican Region (South Africa), Western Pacific Region (Australia and China [Taiwan]), European region (Germany, Greece, Israel, Italy, Spain, and Turkey), in the region of the Americas (Argentina, Canada, and United States).